+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antivenoms: Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • October 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309401

Global Antivenoms Market to Reach $1.8 Billion by 2027

In the changed post COVID-19 business landscape, the global market for Antivenoms estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 7.3% over the analysis period 2020-2027. Snakes, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$1.6 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Scorpions segment is readjusted to a revised 6.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $292.4 Million, While China is Forecast to Grow at 11.1% CAGR

The Antivenoms market in the U.S. is estimated at US$292.4 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$392.1 Million by the year 2027 trailing a CAGR of 11% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4% and 6.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$242.7 Million by the year 2027.

Spiders Segment to Record 6.5% CAGR

In the global Spiders segment, USA, Canada, Japan, China and Europe will drive the 6.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$24.2 Million in the year 2020 will reach a projected size of US$36.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 7.8% CAGR through the analysis period.

Select Competitors (Total 46 Featured) -

  • Boehringer Ingelheim International GmbH
  • BTG PLC
  • CSL Ltd.
  • Merck & Co., Inc.
  • MicroPharm Ltd.
  • Pfizer, Inc.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and a Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Antivenoms

What is the estimated value of the Global Market for Antivenoms?

The Global Market for Antivenoms was estimated to be valued at $1.1 Billion in 2020.

What is the growth rate of the Global Market for Antivenoms?

The growth rate of the Global Market for Antivenoms is 7.3%, with an estimated value of $1.8 Billion by 2027.

What is the forecasted size of the Global Market for Antivenoms?

The Global Market for Antivenoms is estimated to be worth $1.8 Billion by 2027.

Who are the key companies in the Global Market for Antivenoms?

Key companies in the Global Market for Antivenoms include Boehringer Ingelheim International GmbH, BTG PLC, CSL Ltd., Merck & Co., Inc. and Pfizer, Inc..

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Antivenoms - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Antivenoms Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027
  • Table 2: World Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 3: World Historic Review for Antivenoms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 4: World 15-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027
  • Table 5: World Recent Past, Current & Future Analysis for Snakes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 6: World Historic Review for Snakes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 7: World 15-Year Perspective for Snakes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 8: World Recent Past, Current & Future Analysis for Scorpions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 9: World Historic Review for Scorpions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 10: World 15-Year Perspective for Scorpions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 11: World Recent Past, Current & Future Analysis for Spiders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 12: World Historic Review for Spiders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 13: World 15-Year Perspective for Spiders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 14: World Recent Past, Current & Future Analysis for Other Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 15: World Historic Review for Other Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 16: World 15-Year Perspective for Other Species by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 17: World Recent Past, Current & Future Analysis for Polyvalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 18: World Historic Review for Polyvalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 19: World 15-Year Perspective for Polyvalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 20: World Recent Past, Current & Future Analysis for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 21: World Historic Review for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 22: World 15-Year Perspective for Monovalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
  • Table 23: World Recent Past, Current & Future Analysis for Other Anti-Venom Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 24: World Historic Review for Other Anti-Venom Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 25: World 15-Year Perspective for Other Anti-Venom Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • Table 26: USA Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 27: USA Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 28: USA 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 29: USA Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 30: USA Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 31: USA 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
CANADA
  • Table 32: Canada Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 33: Canada Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 34: Canada 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 35: Canada Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 36: Canada Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 37: Canada 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
JAPAN
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
  • Table 38: Japan Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 39: Japan Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 40: Japan 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 41: Japan Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 42: Japan Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 43: Japan 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
CHINA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
  • Table 44: China Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 45: China Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 46: China 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 47: China Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 48: China Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 49: China 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
EUROPE
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • Table 50: Europe Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 51: Europe Historic Review for Antivenoms by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 52: Europe 15-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027
  • Table 53: Europe Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 54: Europe Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 55: Europe 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 56: Europe Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 57: Europe Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 58: Europe 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
FRANCE
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
  • Table 59: France Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 60: France Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 61: France 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 62: France Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 63: France Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 64: France 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
GERMANY
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
  • Table 65: Germany Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 66: Germany Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 67: Germany 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 68: Germany Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 69: Germany Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 70: Germany 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
ITALY
  • Table 71: Italy Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 72: Italy Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 73: Italy 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 74: Italy Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 75: Italy Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 76: Italy 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
UNITED KINGDOM
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
  • Table 77: UK Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 78: UK Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 79: UK 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 80: UK Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 81: UK Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 82: UK 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
SPAIN
  • Table 83: Spain Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 84: Spain Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 85: Spain 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 86: Spain Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 87: Spain Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 88: Spain 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
RUSSIA
  • Table 89: Russia Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 90: Russia Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 91: Russia 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 92: Russia Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 93: Russia Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 94: Russia 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
REST OF EUROPE
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 96: Rest of Europe Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 97: Rest of Europe 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 98: Rest of Europe Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 99: Rest of Europe Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 100: Rest of Europe 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
ASIA-PACIFIC
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Antivenoms by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 103: Asia-Pacific 15-Year Perspective for Antivenoms by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Antivenoms by Species - Snakes, Scorpions, Spiders and Other Species Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 106: Asia-Pacific 15-Year Perspective for Antivenoms by Species - Percentage Breakdown of Value Sales for Snakes, Scorpions, Spiders and Other Species for the Years 2012, 2021 & 2027
  • Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • Table 108: Asia-Pacific Historic Review for Antivenoms by Anti-Venom Type - Polyvalent, Monovalent and Other Anti-Venom Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • Table 109: Asia-Pacific 15-Year Perspective for Antivenoms by Anti-Venom Type - Percentage Breakdown of Value Sales for Polyvalent, Monovalent and Other Anti-Venom Types for the Years 2012, 2021 & 2027
AUSTRALIA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2022 (E)
INDIA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2022 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2022 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2022 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Antivenoms Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2022 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Boehringer Ingelheim International GmbH
  • BTG PLC
  • CSL Ltd.
  • Merck & Co., Inc.
  • MicroPharm Ltd.
  • Pfizer, Inc.